anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs, particularly fenofibrate, are provided. The compositions comprise a therapeutically effective amount of an active agent and a solubilizer. The solubilizer is selected to effectively solubilize active agent in the composition. The solubilizers employed as part of the invention include: a vitamin E substance; monohydric alcohol esters such as trialkyl citrates, lactones and lower alcohol fatty acid esters; nitrogen-containing solvents; phospholipids; glycerol acetates such as acetin, diacetin and triacetin; glycerol fatty acid esters such as mono-, di- and triglycerides and acetylated mono- and diglycerides; propylene glycol esters; ethylene glycol esters; and combinations thereof. The pharmaceutical dosage forms contain the compositions in a suitable dosage form unit such as a capsule. Methods of treating patients comprising administering the compositions are also provided.
PURPOSE: A pharmaceutical composition containing an Acorus gramineus Soland. extract exhibiting neuronal death inhibitory activity as an effective ingredient is provided which has no toxicity to human body and is effective in prevention and treatment of cerebral disease caused by neuronal death. CONSTITUTION: Acorus gramineus Soland. is extracted in water, lower alcohol, hexane, ethyl acetate or a mixture thereof, concentrated and then freeze dried, wherein the lower alcohol is selected from the group consisting of methanol, ethanol and butanol. For example, 1kg Acori graminei Rhizoma is extracted with 2L methanol aqueous solution with a sonicator for 15min two times to produce 3L extract, which is filtered, and concentrated. Thereafter, 100mg extract is mixed with 3.0mg sodium metabisulfite, 0.8mg methyl paraben, 0.1mg propyl paraben and a suitable amount of sterilized distilled water.
INTRODUCTION: Non-communicable diseases (NCDs) are a leading cause of mortality, with a projected rise from 38 million in 2012 to 52 million by 2030. Among NCDs, hypertension, diabetes and Chronic Obstructive Pulmonary Disease are the major burdens in healthcare today, requiring long-term therapies and a significant effort in maintaining treatment adherence.
METHODS: A descriptive cross-sectional study design was adopted to determine medication adherence among patients with non-communicable diseases using non-probability, consecutive sampling techniques after ethical approval from same institute (Reference number: 524). Medication adherence was assessed on 322 patients attending the outpatient department, using a structured interview schedule, after getting Ethical approval from the Institution Review Committee. Morisky medication adherence scale (MMAS-4), Culig adherence Scale, and Beliefs about Medications (BMQ) tool were used to determine the adherence level, causes of non-adherence and belief in medication respectively. Data was coded and analysed using SPSS version 16. Descriptive statistics were used to summarise the data.
RESULTS: The study population exhibited a mean age of 58 ± 12.80 years, with male participants 190 (59.01%). The present study revealed that 148 (45.96%) of the participants have a high adherence level to prescribed medication, and 246 (76.40%) strongly believed that without medication they would be very sick and life would be impossible.
CONCLUSIONS: The study found that less than half of participants fully adhered to prescribed medicine, with forgetfulness identified as a primary cause of non-compliance.
The invention relates to the living field of cosmetics, especially to a perfumed soap type mask and a method for preparing the same. The perfumed soap type mask is prepared from vegetable oil, sodium hydroxide, distilled water, dahurian angelica root, largehead atractylodes rhizome, white poria cocos, root of herbaceous peony, radix ampelopsis, borneol, pearl powder, rhizoma typhonii, common bletilla tuber and licorice root in parts by weight. On the basis of a mutual synergistic or resisting effect of the raw materials, the curative effect is enhanced; and the mask is effective in moisturizing the skin, removing freckles and whitening the skin, delaying skin aging, and replenishing qi and enriching the blood. Moreover, any injury on the skin by chemical substances contained in common cosmetics can be prevented; the recovery capability of the skin is enhanced; and the metabolism is improved. Effects of clearing away heat and toxic materials, eliminating carbuncle and stagnation, removing freckles and whitening the skin, and moisturizing the skin of the mask based on the formula are highlighted. The perfumed-soap type mask provided by the invention is crystallization of the traditional Chinese culture.
This study aimed to investigate the effectiveness of ESWT applied to trigger points on pain, function, and effusion in individuals diagnosed with shoulder impingement syndrome.

This was a randomized controlled clinical trial with a total of 32 which were randomly divided into two equal groups (ESWT Group (EG), n = 16; Control Group (CG), n=16). The participants in the EG were given Extracorporeal Shock Wave Therapy to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles for a total of 5 sessions in 3 weeks (2 sessions in the first week, 2 sessions in the second week, 1 session in the third week) in addition to conventional treatments , while CG received only conventional treatment for five days per week for 3 consecutive weeks. Conventional treatment consist of Ultrasound treatment (Gymna Pulson200) (1 mHz. treatment dose average 1.5 w/cm², intermittent with a small head (50%), 5 minutes ) around the glenohumeral joint of the cases in both groups participating in the study; at an intensity that the patient can tolerate, covering the painful area TENS (modified biphasic asymmetric pulse, and it was set to a pulse width of 100 μs and a frequency of 100 Hz, 20 min,) (Hometech ht 66b) applied; hotpack and exercises (posterior capsule stretching, wand exercises, mobilization approximately 60 minutes of conventional treatment consisting of exercises and shoulder isometric exercises) was applied once a day, 5 times a week in both groups. In addition to conventional physiotherapy. additional to conventional treatment EG was applied 1000 pulses to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles, 500 pulses to the surrounding area, 2 bars, ESWT (GYMNMA Shockmaster 500) was applied for a total of 5 sessions in 3 weeks (2 sessions in the first week, 2 sessions in the second week, 1 session in the third week) at 10 Hz, medium energy level (\<0.28 mJ/mm2).Supraspinatus tendon thickness and effusion of the cases included in the study were evaluated by ultrasonography before and after the treatment(3 weeks) by the same specialist physician who was blind to the groups. Normal joint range of motion by universal goniometer, muscle strength by manual muscle test, posture evaluation by Corbin posture analysis, pain evaluation by Visual Analogue Scale (VAS), functional evaluation by Constant Murley Score (CMS), Arm Shoulder and Hand Problems Questionnaire (DASH) by physiotherapist It was evaluated before and after the treatment (3 weeks).
Patients with melanoma of the trunk or extremities were prospectively enrolled in this trial. Patients with head and neck melanoma were excluded from this study based on our pilot experience. ICG is poorly visualized through muscle, and there seems to be high background uptake in the parotid gland; both of these features limit the utility of ICG and fluorescence imaging. All subjects had T1b or greater melanoma, and met current National Comprehensive Cancer Network (NCCN) guidelines for sentinel node biopsy. All subjects had injection of tech99 and lymphangiography prior to surgery, and injection of indocyanine green (ICG) and methylene blue dye (MB) in the operating room. We utilized methylene blue dye for all subjects due to poor availability of isosulfan blue for a period of time, and to maintain consistency in the trial. Up to 1ml of MB was injected, and 0.9ml ICG (2.5 mg/ml). The ICG and MB were injected into the dermis separately, after induction of anesthesia and prior to prepping the patient.

Each lymph node basin was examined with the gamma probe and imaged with the SPY Elite (Novadaq) prior to making skin incision, with assessment of the visibility of ICG through the skin (yes or no). Once incision was made, the basin was periodically imaged with SPY, or dissection was carried out with real time lymphangiography until the sentinel node was identified. The camera of the SPY machine is positioned over the basin, with the image projected onto a monitor. Similar to laparoscopy, the surgeon can watch the image and operate at the same time. Each sentinel node was assessed for the presence of each dye. A lymph node with any one of the dyes present was considered a sentinel node, and was resected. Fluorescence and blue dye were measured as yes or no, and not quantitated. Additional data collected includes demographic data, the dose of ICG and MB given, adverse effects from any dye, the total number of sentinel nodes identified and the number of malignant sentinel nodes. Pair-wise comparisons were made between the three dyes regarding the number of detected sentinel nodes, and the number of detected metastatic nodes.
This study aimed to compare the efficacy and safety of eltrombopag plus diacerein vs eltrombopag alone in patients with primary immune thrombocytopenia (ITP) who were previously unresponsive to 14 days of eltrombopag treatment at the full dose. Recruited patients were randomly assigned 1:1 to receive either eltrombopag plus diacerein (n = 50) or eltrombopag monotherapy (n = 52). Overall response rate, defined as a platelet count of ≥30 × 109/L, at least doubling of the baseline platelet count, and no bleeding, was reached in 44% of patients in the eltrombopag plus diacerein group compared with 13% in the eltrombopag group at day 15 (P = .0009), and reached in 42% of patients in the combination group compared with 12% in the monotherapy group at day 28 (P = .0006). The addition of diacerein to eltrombopag also led to a longer duration of response (P = .0004). The 2 most common treatment-emergent adverse events were respiratory infection and gastrointestinal reactions in the combination group, and fatigue and respiratory infection in the eltrombopag group. In conclusion, eltrombopag plus diacerein was well tolerated, and induced higher overall response rates and longer duration of response than eltrombopag alone, offering a rejuvenating salvage therapy for patients with ITP unresponsive to 14 days of full dosage eltrombopag. Our work has the potential to enhance the care of patients treated with thrombopoietin receptor agonists, reducing the need for rapid transitions to less-preferable therapies. This study is registered at ClinicalTrials.gov as #NCT04917679.
Subjects randomized to exercise training will participate in a three-month treadmill exercise program in 1-hour training sessions three times per week as previously described. After a 5-minute warm-up period, exercise is initiated at a low workload of 2 mph at 0% grade. Subjects walk until moderate claudication severity develops, and then rest until the discomfort resolves, repeating until the total exercise period is completed. The intensity of the treadmill exercise is increased as tolerated by increasing walking speed by 0.5-1 mph and/or grade by 1-2%. Subjects are encouraged to continue the walking program at home for at least 30 minutes on two separate occasions each week.
The present invention relates to a composition for preventing and treating colon cancer containing extract from the thorn of Gleditsia sinensis as an active ingredient. The disclosed composition is highly cytotoxic to colon cancer cells and arrests the cell cycle at G2/M phase, suppressing expression and activation of Cdc25c, Cdc2, and cyclin B which are cell cycle regulators. The composition interferes with the activation of transcription factors, NF-κb and AP-1, inhibits the activation of MMP-9 in colon cancer cells and effectively suppresses metastasis of cancer cells. The composition also promotes the activation of MAPK (mitogen-activated protein kinase), which includes Erk, p38 MAPKinase and JNK, and induces apoptosis of cancer cells. The composition has excellent anticancer activity even on the individual animal level. In addition, the disclosed composition is extremely safe since it contains extract from the thorn of Gleditsia sinensis as the active ingredient, which has been used in oriental medicine for a long time.
The invention discloses a PD-L1 targeting polypeptide, a preparation method and application thereof, wherein the polypeptide is represented by the following general formula: x is X  1  X  2  X  3  X  4  X  5  X  6  X  7  X  8  X  9  X  10  X  11  . Wherein X is  1  、X  2  、X  8  、X  11  Is hydrophobic amino acid, X  3  、X  4  、X  5  、X  6  、X  7  、X  9  、X  10  Is a hydrophilic amino acid. The polypeptide provided by the invention can specifically identify and bind to PD-L1 protein. The polypeptide of the invention adopts a chemical synthesis method, has simple preparation, strong specificity, high selectivity, safety and reliability, overcomes the defects of long production period of antibody biological preparations and the like, and can be used for preparing the targeting probe of cancers. The invention can perform immune blocking on PD-L1 protein through immunotherapy, thereby activating the recognition and phagocytosis of tumor cells by an in vivo immune system, effectively inhibiting the growth and metastasis of tumors, and realizing good anti-tumor effect. The polypeptide of the invention can provide effective clinical basis and application value for immunotherapy.
For this single case research design with alternating treatments, 5 control volunteers and 5 participants with severe speech and physical impairment, each with a control partner for partner input will complete a story retell task with BCI-FIT language modeling features on and with BCI-FIT language modeling features off. Outcome measures are information transfer rate and user experience.
PCT No. PCT/JP92/00470 Sec. 371 Date Nov. 15, 1993 Sec. 102(e) Date Nov. 15, 1993 PCT Filed Dec. 23, 1993 PCT Pub. No. WO92/18106 PCT Pub. Date Oct. 29, 1992.The object of this invention is to provide a process for producing a solid dispersion, which has overcome the disadvantages of the conventional production technology for solid dispersions. The invention comprises employing a twin-screw extruder in the production of a solid dispersion. In accordance with the invention, a solid dispersion can be expediently produced without heating a drug and a polymer to or beyond their melting points and without using an organic solvent for dissolving both components and the resulting solid dispersion has excellent performance characteristics.
The present invention relates to a slow-release moclobemide capsule which comprises moclobemide, a blank pill core, a slow-release agent, a plasticizer and an antisticking agent, and the weight ratio of the components is 100 to 111 to (1.9-300) to (0-20). If pulp is prepared by ethanol, the antisticking agent is 1% of the weight of the ethanol, otherwise, the antisticking agent is not used. The preparation technology comprises the following steps that firstly, a core containing a pill is prepared by a granule coating machine; after the core is dried, a slow release coating layer is coated and dried by blast; the present invention can be obtained by loading the core into a hard capsule casing. The present invention has the characteristics of good therapeutic effect and quick action. Except the action of resisting depression, the present invention also has effect to phobia and anxiety neurosis. The present invention can improve cognitive function, and can also be used for treating disease of senile dementia. The medicine has less side effect, and the use is safe and reliable. Patients have good tolerance to the medicine, and rarely generate the anticholinergic effect generated by other antidepressants after taken the medicine. The medicine can slowly release and maintain stable blood medicine concentration and long action time, and has the advantages of side effect reduction and convenient admittance.
BACKGROUND: We analysed the COMparison Between All immunoTherapies for Multiple Sclerosis (NCT03193866), a Swedish nationwide observational study in relapsing-remitting multiple sclerosis (RRMS), to identify trajectories of fatigue and their association with physical disability following start of disease-modifying therapy (DMT).
METHODS: Using a group-modelling approach, we assessed trajectories of fatigue with the Fatigue Scale for Motor and Cognitive Functions and physical disability with Expanded Disability Status Scale among 1587 and 1818 individuals who initiated a first DMT and had a first DMT switch, respectively, followed during 2011-2022. We investigated predictors of fatigue trajectories using group membership as a multinomial outcome and calculated conditional probabilities linking membership across the trajectories.
RESULTS: We identified five trajectories of fatigue in participants who initiated their first DMT: no fatigue (mean starting values=23.7; 18.2% of population), low (35.5; 23.9%), mild (49.0; 21.6%), moderate (61.3; 20.1%) and severe (78.7; 16.1%). While no, low, mild and severe fatigue trajectories remained stable, the moderate trajectory increased to severe fatigue. Similarly, we identified six fatigue trajectories among participants who did a DMT switch, all indicating stable values over time. Women initiating a first DMT were more likely than men to display a severe fatigue trajectory, relative to the no fatigue one. There was a strong association between fatigue and physical disability trajectories.
CONCLUSIONS: In this cohort of people with actively treated RRMS, self-reported fatigue remained stable or increased over the years following DMT start. There was a strong association between fatigue and disability after DMT start.
The intervention period will last 4 weeks, with a periodicity of 2 weekly sessions of 50 minutes each. The intervention of the experimental group will consist of a protocol using myofascial and proprioceptive neuromuscular facilitation techniques.
The primary goal of palatoplasty is the restoration of normal speech, that can be aimed by, among many procedures, lengthening the palate through the pushback technique; one of its complications is abnormal maxillary growth. The main factor affecting facial growth in CLP patients is believed by many to be the palatoplasty-due to the large scar retraction resulting from some surgical techniques. The non-crosslinked two-layer bioabsorbable collagen matrix Mucograft™ (Geistlich Pharma AG, Wolhusen, Switzerland) is a potential tool to aid in wound closure in a second-intention healing situation. The objective of this work was to test the use of an acellular dermal matrix (Mucograft®) in an experimental model of Veau-Wardill-Kilner palatoplasty, as a tool to reduce scar retraction of the denuded palatine mucosa. Twenty-four 3-week-old male Wistar rats were used. The animals were randomly divided into two groups. In the control group, an excision was made with bone exposure in the palate, simulating the defect left in the Veau-Wardill-Kilner palatoplasty. In the intervention group, the same procedure was performed, and the area of denuded palatine bone was treated with a bioabsorbable collagen matrix (Mucograft®). For data collection, 9 weeks after surgery (12 weeks of life), the animals were euthanized by excessive anesthetic dosage. Maxillary growth, macroscopic appearance of the scar, pain, and bleeding were evaluated. There were significant statistical differences between the groups for palate length growth (7.6 mm + -0.38 mm vs 5.5 mm + -0.36 mm, P = .009) and for palate width growth (1.47 mm + -0.8 mm vs -0.09 mm + -0.55 mm, P = .001), favoring dermal matrix group compared to controls. Whereas for pain and bleeding, there were no differences between the groups. The use of dermal matrix in rats with an area of bone denudation on the palate increases maxillary length and width growth patterns. Besides, it does not increase pain, bleeding, or post-operative complications.
In the previous "Icemelting" trial, neoadjuvant anti-PD-1 plus anti-VEGFR therapy was used in 20 patients with locally advanced and resectable oral squamous cell carcinoma (OSCC), and the neoadjuvant therapy was well-tolerated, with no grade 3-4 toxicity. The MPR rate was 40% (8/20), including 5% (1/20) pathological complete response; furthermore, in the patients with CPS\>10, the MPR rate was 100%. As we know, the MPR might transfer to survival benefit in the patients received neoadjuvant therapy. Therefore, in this randomized phase II trial, we aimed to evaluate the survival benefit of neoadjuvant anti-PD-1 plus anti-VEGFR therapy in the patients with locally advanced OSCC and CPS\>10 (Icemelting-2 trial). A total of 46 patients will be enrolled in this trial, and the primary endpoint is 2-year disease-free survival rate. The neoadjuvant therapy arm will receive three cycles of Carrelizumab plus Apatinib with 14 days each, followed by the standard treatment of surgery and postoperative adjuvant therapy. The control arm will received the standard treatment of surgery and postoperative adjuvant therapy.
The invention discloses a traditional Chinese medicine composition for improving sleep and a preparation method and application thereof. The traditional Chinese medicine composition comprises, by weight, 10-25 parts of wrinkled gianthyssop herb, 10-25 parts of fortune eupatorium herb, 25-40 parts of silktree albizzia flower, 2-7 parts of agilawood, 4-10 parts of frankincense and 4-10 parts of myrrh. The composition may also comprise Prunellae Spica, Os Draconis, Concha Ostreae, flos Chrysanthemi, ramulus Uncariae cum uncis, Succinum powder, cortex et radix Polygalae, Poria, rhizoma Acori Graminei, radix Curcumae, and flos Rosae Rugosae. The traditional Chinese medicine prescription is prepared by combining and matching agastache rugosus, eupatorium fortunei, flos albiziae, agilawood, frankincense and myrrh, and on the basis, proper traditional Chinese medicinal materials can be added and subtracted according to the specific manifestation difference of insomnia accompanied symptoms. The composition formula suitable for insomnia patients with various accompanying symptoms is obtained. Clinical tests show that the traditional Chinese medicine composition has the effect of improving sleep which is not inferior to that of oral medicines, and has quick response and no toxic or side effect.
Cirsium japonicum Fisch. ex DC. (CF) and Cirsium setosum (Willd.) MB (CS) are commonly used clinically to stop bleeding and eliminate carbuncles. Still, CF is mainly used for treating inflammation, while CS favors hemostasis. Therefore, the present study used UHPLC-MS to analyze the main chemical constituents in CF-CS extract. We optimized the extraction process using single-factor experiments and response surface methodology. Afterward, the hemostatic and anti-inflammatory effects of CF-CS extract were investigated by determining the clotting time in vitro, the bleeding time of rabbit trauma, and the induction of rabbit inflammation using xylene and lipopolysaccharide. The study of hemostatic and anti-inflammatory effects showed that the CF-CS, CF, and CS extract groups could significantly shorten the coagulation time and bleeding time of rabbits compared with the blank group (p < 0.01); compared with the model group, it could dramatically inhibit xylene-induced ear swelling in rabbits and the content of TNF-α, IL-6, and IL-1β in the serum of rabbits (p < 0.01). The results showed that combined CF and CS synergistically increased efficacy. CF-CS solved the problem of the single hemostatic and anti-inflammatory efficacy of a single drug, which provided a new idea for the research and development of natural hemostatic and anti-inflammatory medicines.